Straits Times Index
3,384.29 +20.61 (+0.61%) Nikkei
27,509.46 +107.41 (+0.39%) Hang Seng
21,660.47 -297.89 (-1.36%) FTSE 100
7,901.80 +81.64 (+1.04%) BTC-USD
23,197.14 -257.80 (-1.10%) CMC Crypto 200
535.42 -1.43 (-0.27%)
Roche Holding AG (RHHVF)
| Previous close | 301.33 |
| Open | 302.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 302.00 - 306.83 |
| 52-week range | 298.00 - 430.00 |
| Volume | |
| Avg. volume | 6,596 |
| Market cap | 245.728B |
| Beta (5Y monthly) | 0.21 |
| PE ratio (TTM) | 16.14 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 9.97 (3.24%) |
| Ex-dividend date | 17 Mar 2022 |
| 1y target est | N/A |
- Zacks
Roche's (RHHBY) 2022 Core Earnings Grow, 2023 Outlook Dismal
Roche's (RHHBY) performance in 2022 was sub-par as demand for COVID-19-related products declined significantly and 2023 will also be impacted.
- Reuters
Roche warns 2023 profits will fall on $5 billion COVID sales hit
Roche warned on Thursday profits will decline in 2023 as falling demand for its COVID-19 therapy and diagnostics kits will knock sales by over $5 billion, the latest sign that the pharmaceutical industry's years-long pandemic boost is ebbing. Sales and core earnings per share were expected to decrease at a "low single-digit" percentage this year, the Swiss pharmaceuticals and diagnostics company said in a statement. COVID-related sales, mainly from lab testing and antibody treatment Ronapreve, are seen falling by 5 billion Swiss francs ($5.5 billion) for the full year, it said.
- Zacks
Roche (RHHBY) Tecentriq Meets Adjuvant Liver Cancer Study Goal
Roche's (RHHBY) phase III IMbrave050 study, evaluating Tecentriq plus Avastin for treating early-stage hepatocellular carcinoma, meets its primary endpoint.
